<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1462">
  <stage>Registered</stage>
  <submitdate>19/07/2006</submitdate>
  <approvaldate>20/07/2006</approvaldate>
  <actrnumber>ACTRN12606000308594</actrnumber>
  <trial_identification>
    <studytitle>A randomised double blind placebo controlled clinical trial of the efficacy of an Australian naltrexone implant compared to oral naltrexone for the long-term management of heroin-dependent persons</studytitle>
    <scientifictitle>A randomised double blind placebo controlled clinical trial of naltrexone implants for the treatment of heroin addiction</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Heroin dependence</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Addiction</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A randomised, double placebo, double blind trial comparing the ONeil long acting naltrexone subcutaneous implant (3.6g release rate 0.4% / day) plus placebo capsule with placebo implant plus capsules containing 50mg naltrexone hydrochloride. Participants will receive the intervention and data will be collected for a total of 6 months.</interventions>
    <comparator>Double Placebo</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Proportion with blood naltrexone concentrations above therapeutic levels (2 ng/ml)</outcome>
      <timepoint>Measured at 1, 2, 3, 4, 5, &amp; 6 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of accidental opiate overdoses (hospital admissions or ED presentations) to 6 months</outcome>
      <timepoint>baseline to 6 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Opiate related morbidity (hospital admissions) and mortality to 6 months</outcome>
      <timepoint>baseline to 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Craving for heroin questionnaire (Tiffany). </outcome>
      <timepoint>Measured at 0, 1, 2, 3, 4, 5, &amp; 6 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion returning to dependent heroin/opiate use (DSM IV criteria).</outcome>
      <timepoint>At 6 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Frequency of other drug use.</outcome>
      <timepoint>At 0, 1, 2, 3, 4, 5, &amp; 6 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Other drug related accidental overdose, other morbidity (hospital admission or ED presentation) or mortality to 6 months</outcome>
      <timepoint>baseline to 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Opiate Treatment Index scores.</outcome>
      <timepoint>At 0, 1, 2, 3, 4, 5, &amp; 6 months.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Heroin dependence (DSM-IV criteria which covers the previous 12 months)Resident in the Perth (Western Australia) metropolitan area or regional areas with approved study support services Willing and able to provide written informed consentWilling to be randomised to either arm of the studySatisfactory completion of screening questionnaire.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>High risk of overdose (3+ overdoses in previous month)Non compliant with oral naltrexone (4 + times in last 3 months) or prior implantPregnancyContra indications or prior adverse reactions for study medications/procedures.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Numbered containers</concealment>
    <sequence>Randomisation was based on computer generated random numbers, using a variable block size with a unified allocation ratio</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>4/01/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>70</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Western Australia</primarysponsorname>
    <primarysponsoraddress>35 Stirling Highway</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health &amp; Medical Research Council</fundingname>
      <fundingaddress>Canberra</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>n/a</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>GoMedical Industries has developed a formulation of sustained release naltrexone, suitable for subcutaneous depot administration. Currently, implants are inserted by minor surgery under local anaesthetic in high risk patients under the Therapeutic Goods Administration (TGA) Special Access Category A scheme (SAS) through the Australian Medical Procedures Research Foundation (AMPRF), Western Australia. Although there is a preliminary basis for believing that this naltrexone implant treatment may offer significant benefits over oral and other naltrexone depot preparations thus far reported for managing the heroin dependent patient, this needs to be verified through a clinical trial. Hence, the main objective of this study is to provide rigorous clinical data using a double blind, double placebo controlled study, on the effectiveness of this naltrexone implant compared to oral naltrexone in the management of heroin dependent persons by primarily monitoring: maintenance of blood naltrexone and 6-b-naltrexol concentrations above therapeutic levels; prevention of accidental opiate overdose; reduced opiate use; reduced opiate related morbidity and mortality; reduced craving for heroin and other health related outcomes.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>University of Western Australia HREC</ethicname>
      <ethicaddress>35 Stirling Highway,
Crawley</ethicaddress>
      <ethicapprovaldate>29/03/2004</ethicapprovaldate>
      <hrec>RA/4/1/0739</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Gary Hulse</name>
      <address>School of Psychiatry &amp; Clinical Neurosciences 
University of Western Australia
QE II Medical Centre MPC 521
Nedlands Perth </address>
      <phone>+61 8 9346 2280</phone>
      <fax>+61 8 9346 3828</fax>
      <email>gary.hulse@uwa.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Robert Tait</name>
      <address>School of Psychiatry &amp; Clinical Neurosciences, 
University of Western Australia,
QE II Medical Centre, MPC 521,
Nedlands, Perth SA</address>
      <phone>+61 8 9346 2281</phone>
      <fax>+61 8 9346 3828</fax>
      <email>robert.tait@uwa.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>